The Life Sciences Report
For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.
The Approval Process in Action
Source: The Life Sciences Report and Visual Capitalist (5/1/13)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
Notable Quotes
Can-Fite BioPharma Ltd. "CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) - The Life Sciences Report Interview with Reni Benjamin More >
Sunesis Pharmaceuticals Inc. "There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) - The Life Sciences Report Interview with Mara Goldstein More >
Neuralstem Inc. "If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) - The Life Sciences Report Interview with Edward Stopke More >
Athersys Inc. "ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) - The Life Sciences Report Interview with Edward Stopke More >
Rexahn Pharmaceuticals Inc. "The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) - The Life Sciences Report Interview with Edward Stopke More >